Article Text

Download PDFPDF
To scan or not to scan your Parkinson patient: that is the question!
  1. Rui Araújo1,2,3,
  2. Anouke van Rumund3,
  3. Bastiaan R Bloem3
  1. 1 Neurology, Centro Hospitalar e Universitario São João E.P.E, Porto, Portugal
  2. 2 Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Porto, Portugal
  3. 3 Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands
  1. Correspondence to Professor Bastiaan R Bloem, Radboudumc, Nijmegen 6500 HB, The Netherlands; bas.bloem{at}radboudumc.nl

Statistics from Altmetric.com

The diagnosis of Parkinson’s disease (PD) is primarily a clinical exercise.1 Structural imaging is not recommended in cases with a typical presentation, and should remain reserved for those patients where there is reasonable doubt about the clinically based diagnosis.2 This is not uncommon: even in tertiary specialised centres, up to 25% of patients initially diagnosed with PD are reclassified at follow-up.3 Triggers to reconsider the diagnosis include presence of absolute exclusion criteria (such as cerebellar ataxia) or development of multiple features that jointly signal the presence of a form of atypical parkinsonism (‘red flags’). If neuroimaging is deemed necessary, brain MR is generally preferred over brain CT because of the superior resolution and sensitivity.4

Dopamine transporter single-photon emission CT (DaTscan) allows assessment of the nigrostriatal dopaminergic system, and more specifically, the intactness of the presynaptic dopaminergic terminals. Its availability may be limited to tertiary centres, and not all countries have access to DaTscans. Its usefulness in the investigation of a patient with parkinsonism is relatively limited, since it cannot differentiate between different forms of degenerative parkinsonism (ie, PD and progressive supranuclear palsy).1 Nonetheless, it can differentiate essential tremor from PD (for which it is licensed in Europe and the USA) and can also differentiate degenerative forms of parkinsonism from drug-induced parkinsonism (the latter presenting with a normal DaTscan).2 In our clinical practice, only a select group of patients receives a DaTscan, usually younger patients with …

View Full Text

Footnotes

  • Contributors RA prepared the original draft and provided significant input to later versions of the manuscript. AvR provided significant contributions to earlier versions of the manuscript. BB provided the idea for the manuscript, contributed to its early design and reviewed the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned. Externally peer-reviewed by Simon Lewis, Sydney, Australia, and Ed Newman, Glasgow, UK.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • A difficult case
    Lou Wiblin Dipayan Mitra Naomi Warren